Xu Hao, Hu Xiaomu, Wang Biyun, Sun Ying, Wang Ye, Tang Qisheng, Zhu Qiongji, Song Kun, Chen Hong, Chen Lingchao, Cheng Haixia, Qin Zhiyong
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
National Center for Neurological Disorders, Shanghai, China.
Exp Hematol Oncol. 2025 Jun 13;14(1):84. doi: 10.1186/s40164-025-00677-w.
H3K27-altered diffuse midline gliomas (H3-DMGs) represent aggressive tumors with fatal outcome and exceedingly rare cases have a long-term survival (LTS). We included 5 adult thalamic H3-DMG LTS and 13 short-term survivors (STS), and performed whole exome sequencing, RNA-seq and DNA methylation array. The median overall survival was 48.0 ± 12.1 months for LTS and 12.5 ± 5.9 months for STS. There was no significant difference in clinical characteristics and treatment received between LTS and STS. LTS exhibited more copy number gain and amplification ( = 0.007), and tumor microenvironment analysis revealed increased accumulation of M1 macrophage ( = 0.005) alongside a notable reduction in cancer-associated fibroblast in LTS ( = 0.037). The signatures of LTS and STS were signature 30 (similarity = 76.7%) and signature 6 (81.8%), respectively. Of note, LTS exhibited hypermethylated CpG island ( = 0.002). Additionally, we demonstrated that LTS and STS could be distinguished using differentially methylated probes. Collectively, the present study delineated unique molecular characteristics of LTS H3-DMG.
The online version contains supplementary material available at 10.1186/s40164-025-00677-w.
H3K27改变的弥漫性中线胶质瘤(H3-DMG)是具有致命结局的侵袭性肿瘤,极少数病例有长期生存(LTS)。我们纳入了5例成年丘脑H3-DMG长期生存者和13例短期生存者(STS),并进行了全外显子测序、RNA测序和DNA甲基化阵列分析。长期生存者的中位总生存期为48.0±12.1个月,短期生存者为12.5±5.9个月。长期生存者和短期生存者在临床特征和接受的治疗方面无显著差异。长期生存者表现出更多的拷贝数增加和扩增(=0.007),肿瘤微环境分析显示M1巨噬细胞积累增加(=0.005),同时长期生存者中癌症相关成纤维细胞显著减少(=0.037)。长期生存者和短期生存者的特征分别为特征30(相似度=76.7%)和特征6(81.8%)。值得注意的是,长期生存者表现出CpG岛高甲基化(=0.002)。此外,我们证明可以使用差异甲基化探针区分长期生存者和短期生存者。总体而言,本研究描绘了长期生存的H3-DMG的独特分子特征。
在线版本包含可在10.1186/s40164-025-00677-w获取的补充材料。